NATEGLINIDE IS HIGHLY BOUND TO PLASMA PROTEINS (98%), MAINLY ALBUMIN. IN VITRO DISPLACEMENT STUDIES WITH HIGHLY PROTEIN-BOUND DRUGS SUCH AS FUROSEMIDE, PROPRANOLOL, CAPTOPRIL, NICARDIPINE, PRAVASTATIN, GLYBURIDE, WARFARIN, PHENYTOIN, ACETYLSALICYLIC ACID, TOLBUTAMIDE, AND METFORMIN SHOWED NO INFLUENCE ON THE EXTENT OF NATEGLINIDE PROTEIN BINDING. SIMILARLY, NATEGLINIDE HAD NO INFLUENCE ON THE SERUM PROTEIN BINDING OF PROPRANOLOL, GLYBURIDE, NICARDIPINE, WARFARIN, PHENYTOIN, ACETYLSALICYLIC ACID, AND TOLBUTAMIDE IN VITRO . CERTAIN DRUGS, INCLUDING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS), SALICYLATES, MONOAMINE OXIDASE INHIBITORS, AND NON-SELECTIVE BETA-ADRENERGIC-BLOCKING AGENTS MAY POTENTIATE THE HYPOGLYCEMIC ACTION OF NATIZ AND OTHER ORAL ANTIDIABETIC DRUGS. CERTAIN DRUGS INCLUDING THIAZIDES, CORTICOSTEROIDS, THYROID PRODUCTS, AND SYMPATHOMIMETICS MAY REDUCE THE HYPOGLYCEMIC ACTION OF NATIZ AND OTHER ORAL ANTIDIABETIC DRUGS.